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 Comorbidity is defined as the presence of one or more additional conditions co-occurring with primary indices.  Comor-
bidity is common in older cancer patients. Its prevalence, however, is difficult to determine and varies by cancer site. There 
is no single reason for which comorbidity and cancer coexist, but chronic diseases and cancer are both common in older 
age and share many risk factors. 
 There is no consensus on how should comorbidity be measured. Even though many comorbidity indices have been 
developed so far, no unified, widely used instrument exists. 
 Patients with comorbidities have worse outcomes compared to those with no such conditions. They may experience 
diagnostic and therapeutic delay and be disqualified from radical treatment more often. Moreover, they are more likely 
to suffer from treatment-related complications and have worse overall survival.
 It seems important to assess the comorbidity status as a part of individualised oncologic treatment planning. However, 
as data regarding its significance are insufficient and in many cases conflicting, patients with comorbidity should not be 
routinely considered as not fit enough for a radical treatment. Therefore, to adequately address all of the concerns that 
have been raised, a broader participation of older, comorbid patients in clinical trials is needed.
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Introduction
Almost all chronic diseases are more prevalent in elderly than 
younger individuals, and so is cancer. That is why taking care 
of oncology patients who suffer from multiple, concurrent 
comorbidities is an everyday job [1]. Nevertheless, such pa-
tients are still often excluded from randomised controlled 
trials, making it difficult to generalise results and establish 
relevant clinical guidelines [2]. This, in turn, leads to diagnostic 
and treatment dilemmas. Older patients with comorbidity are 
often disqualified from radical therapy, receive suboptimal 
care, and suffer from various adverse events: prolonged ho-
spitalisation, institutionalisation, decreased quality of life, and 
higher complication rates and mortality [3]. Despite the fact, 
that comorbidity is considered important by most clinicians, 
there is no consensus on definition, way to measure it, and its 
role in geriatric assessment. It also often gets confused with 
other terms, which are related to but not synonymous with 
comorbidity, such as multimorbidity, polypharmacy, frailty or 
disability [1]. 
Definition and etiology
The problem of comorbidity was firstly addressed in 1970 by 
Feinstein, who noticed its influence on the diagnostic and 
therapeutic process and defined it as “any distinct additional 
clinical entity that has existed or that may occur during the 
clinical course of a patient that has the index disease under 
study” [4]. Since that time, the term has been used in multiple 
studies indicating either a disease coexisting with the primary 
disorder simultaneously, but independently, or every additional 
condition, even one related to the “index” disease. The concept 
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1.  What is the cancer site? As some of the measures have 
been developed specifically for a particular disease, it se-
ems appropriate to use them if applicable.
2.  What is the endpoint to predict? The indices have 
been developed to predict different outcome measures 
e.g. 10-year mortality, cancer survival, postoperative mor-
tality etc. It would be reasonable to use the index with 
the highest possible validity for the particular clinical or 
research question.
3.  What kind of data and how much time do we have? 
Some of the indices require a lot of specific information 
that is unavailable or assessment may be too time-con-
suming. The choice should be, though, adjusted to the 
clinical situation or research plan.
Unfortunately, there is still a great inconsistency in appro-
ach to the analysis of comorbidity status. The prognostic value, 
validity, reliability and feasibility of different measures is often 
questioned, making clinicians unclear about their usefulness 
and generally unwilling to use them on a regular basis [16].
Epidemiology
The burden of comorbidity in older cancer patients is of in-
creasing concern. Its prevalence is generally high, but differs 
depending on the population included and research metho-
dology (e.g. type of cancer, age range, way in which comor-
bidity was assessed). Regarding lung cancer, in patients aged 
≥70 several authors reported that 80–83% of patients had 
CCI ≥1 [17–19]. In oesophageal cancer patients aged ≥65, 
prevalence of comorbidity (CCI ≥1) was also high and ranged 
from 70–80% depending on the study [20–22]. Among indi-
viduals aged 65 or more suffering from head and neck cancer, 
Dziemiańczyk-Pakieła et. al. reported comorbidity in 62% of 
patients, based on a list of diagnoses available in medical re-
cords [23]. In older patients with colon cancer (≥65 y), however, 
comorbidity (CCI ≥1) was present less often as its’ prevalence 
ranged from 32–52% [24–26]. In a US study of 49 616 women 
with breast cancer, 23% of patients aged 85–89 and 11% of 
patients aged 67–69 had severe comorbidity (CCI ≥2) [27]. In 
general, studies with more inclusive measures of comorbidity 
show a higher percentage of affected patients. It also seems 
to be more common in those with certain cancer types, espe-
cially smoking-related cancers such as lung, head and neck or 
bladder cancer [28], and in reports based on questionnaires or 
review of medical notes, rather than in those based on admi-
nistrative data [29–31]. Analysis of the prevalence of different 
types of comorbidity is difficult, as most authors uses indexes, 
rather than list all of the the diagnoses. Most likely, however, 
the spectrum of diseases coexisting with cancer reflects the 
distribution of disorders in the general populations of the el-
derly. For example, in a Dutch registry of patients with breast, 
lung, colorectal, prostate and ovarian cancer aged ≥70, most 
common were heart disease, cerebrovascular and peripheral 
vascular disease, hypertension, pulmonary disease and diabe-
of comorbidity is important not only in clinical medicine, but 
also in public health and epidemiology, which explains the 
need for different definitions and approaches to its measure-
ment [5]. For the clinicians’ purposes, it seems most appropriate 
to acknowledge that comorbidity is the presence of one or 
more additional conditions co-occurring with a primary 
condition. Regarding oncological patients, in most cases 
cancer is considered the primary, index disease, while other 
disorders are named as comorbidities.
Considering the etiology of comorbidity, Valderas et. al. 
[5] suggested five main pathways in which the co-existing 
diseases may be associated: 
1. There is no etiological association between the diseases 
(two diseases occur by chance e.g. lung cancer and pso-
riasis) 
2. One of the diseases is a direct cause of the other (e.g. brain 
tumor and epilepsy)
3. The risk factors for each disease are correlated (e.g. risk 
factor1: smoking → disease1: chronic pulmonary obstruc-
tive disease; risk factor2: alcohol→ disease2: Hepatocellular 
carcinoma)
4. The risk factors for each disease are not correlated, but 
each can cause either disease (e.g. risk factor 1: smoking; 
risk factor 2: age, disease 1: ischaemic heart disease; disease 
2: lung cancer)
5. The symptoms of each disease are in fact all caused by 
another, undiagnosed disease (e.g. disease1: tension he-
adaches, disease2: hypertension, disease 3: pheochromo-
cytoma) [5].
In older patients, however, such interrelations are difficult 
to follow, as their comorbidities are often multiple, long-lasting 
and co-exist with functional decline. Nevertheless, looking for 
possible causes and associations between particular condi-
tions is essential, as in some cases the onset of comorbidity 
can be predicted, or a single intervention may address more 
than one health issue. It is also worth mentioning that oncolo-
gical treatment itself may cause or worsen comorbidity. While 
cancer often becomes a chronic condition, this mechanism 
seems to be of growing importance [1].
How can we measure comorbidity?
There is no “gold standard” regarding comorbidity measurement, 
as none of the existing approaches is optimal for all purposes. 
The simplest way is to divide patients into two groups: with 
or without comorbidity; or to simply count the prevalence of 
all comorbid conditions. However, defining what a comorbid 
condition is may be difficult, resulting in weak repeatability and 
the poor prognostic value of this approach. The problem may 
be solved by the use of comorbidity indices. The most popular 
ways to quantify the problem of comorbidity are simple condi-
tion counts, organ-based systems or weighted indices (Tab. I).
While choosing the measure of comorbidity, the key con-
siderations are [16]:
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tes [32]. In recent years, researchers have also tried to examine 
so-called patterns of comorbidity, as certain diseases seem to 
occur in typical clusters (e.g. cardiopulmonary, cardiovascular, 
metabolic, neurological/mental health etc.). This approach may 
facilitate development of prevention strategies and clinical 
practice guidelines, but considering older cancer patients, the 
existing data is still insufficient [33, 34].
How does comorbidity affect cancer outcomes?
Cancer outcomes may be influenced by comorbidity on many 
levels, starting from screening and detection, through choice of 
treatment, adherence and compliance, ending with treatment 
response and complications. 
The presence of comorbid conditions may blur the 
classical clinical presentation of cancer,  resulting in dia-
gnostic delay. It is no surprise that diseases like dementia, 
alcohol dependence or other psychiatric disorders have been 
associated with late cancer diagnoses [33]. Also, the greater 
number of comorbid conditions has been shown to be as-
sociated with longer cancer diagnostic intervals [35]. As 
physicians are usually focused mostly on the chief complaint, 
comorbid patients may receive screening procedures less 
often. For example, that is why in a Canadian cross-sectional 
study, patients with depression were found to receive colorec-
tal cancer screening recommendations less often [36]. With 
fewer resources and social support, older patients with chronic 
diseases may also experience difficulties with travelling to 
medical facilities. Moreover, such individuals (especially the ol-
dest) may be simply less interested in undergoing life prolonging 
procedures [37]. On the other hand, comorbid patients are more 
likely to use medical services. They may undergo preventive fol-
low-ups more often and so benefit  from oncological alertness. 
This positive impact, however, seems only to occur in certain 
comorbidity types. Fleming et al. reported that women who had 
cardiovascular, musculoskeletal, gastrointestinal, genitourinary 
disease, or osteoarthritis had 7%–24% lower risk of developing 
Table I. A summary of the characteristics of frequently used comorbidity indices
Index name Author, year Clinical purpose Items included Severity of 
assessed items
Scoring Score range
ASA Saklad et al., 1941
Last Amended: 
ASA House of Delegates, 
2019 [6]
to assess and communicate 
a patient’s pre-anesthesia 
comorbidities. The classification 
system alone does not predict 
the perioperative risks
overall physical 
status
does not apply does not 
apply
1–6
CIRS Linn et al., 1968 [7] physical impairment assessment 
for various clinical uses
13/14 systems 0–4 summative 0–56
KFI Kaplan and
Feinstein,
1974 [8]
to predict 5-year mortality due 
to the comorbid conditions  in 
patient with type II diabetes
12 systems 1–3 highest score 1–3
CCI Charlson et al.,
1987 [9]
to predict risk of death from 
comorbid disease during 
10-years follow-up
17 conditions 1–6 summative 0–33
ICED Greenfield et al.,
1993 [10]
to predict the impact of 
comorbidity and functional 
status on the 1-year 
postoperative complications 
and quality of life after total  hip 
replacement
14 systems 
+10 functional 
impairments
0–4 (comorbidity)
0–2 (functional 
status)
highest 
scores of both 
dimensions
0–3
Satariano Index Satariano et al.,
1994 [11]
to predict the effect of 
comorbidity on 3-years survival 
in breast cancer patients
7 conditions unweighted condition 
count
0–7
Elixhauser 
Comorbidity 
Index 
Elixhauser et al.,
1998 [12]
assessment of comorbidity using 
administrative data
30 conditions conditions 
analysed 
separately
does not 
apply
does not 
apply
Elixhauser 
Point System
van Walraven et al.,
2009 [13]
to derive an index from 
Elixhauser conditions
21 conditions β-coefficient summ of 
β-coefficients
–19 to 89
ACE-27 Picirillo et al., 1996 [14] assessment of comorbidity in 
oncological patients
27 conditions 1–3 highest score 
of single item
1–3
CPS Evans et al., 2012 [15] assessment of the severity of 
comorbid conditions in trauma 
patients
all known 
conditions + 
all pre-injury 
medications
unweighted summative 0–n
ASA – American Society of Anesthesiologists Physical Status Classification System; CIRS – Cumulative Illness Rating Scale; KFI – Kaplan-Feinstein Index; CCI – Charlson Comorbidity 
Score; ICED – Index of Coexistent Disease; ACE-27 – Adult Comorbidity Evaluation-27; CPS – Comorbidity-Polypharmacy Score
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advanced breast cancer. Conversely, however, they found those 
with diabetes, renal, endocrine, psychiatric, haematological di-
sease, osteoporosis, obesity and AIDS to be at 11%–20% higher 
risk of being diagnosed with cancer at an advanced stage [38]. 
Other studies analysing the  use of mammography, PSA, Pap 
smear and colorectal cancer screening between patients with 
different comorbidity burdens have also had mixed results, 
reporting either higher or lower risk of being diagnosed with an 
advanced disease [39]. While cancer screening is in many ways 
related to comorbidity status, a common dilemma is whether 
a chronically ill patient may benefit from early cancer detection. 
Unfortunately, as no recommendations are available in this 
matter, they probably often get either under- or over-screened 
[39]. The presence of comorbidity has also been associated with 
prolonged time from diagnosis to treatment, as a certain 
amount of time is needed to consult the patients with other 
specialists or to stabilise their chronic diseases [40].
A general belief that patients with comorbidities have 
poorer overall survival compared to those without co-
morbidities has been confirmed by most researchers. The 
systematic review of observational studies, which analysed 
the impact of comorbidity on  breast, colorectal and lung 
cancer outcomes, showed that in breast cancer patients the 
5–7 years mortality was 1.1 to 5.8-fold higher in patients with 
comorbidity, among patients with colorectal cancer the 5-year 
mortality was 1.2 to 4.8-fold higher, and in lung cancer (1–5 
years follow-up) 1.1 to 1.5-fold higher. The lowest difference 
in survival time in lung cancer patients was most likely due to 
the fact that the effect of comorbidity on the overall mortality 
seems to be more evident in highly curable cancers.  Patnaik 
et al., for example, who analysed a cohort of 64 0034 women 
with  stage I breast cancer (known for its favourable progno-
sis), found that in patients with serious comorbidities, the 
outcomes have not corresponded with survival rates of early-
-stage cancer, but were comparable to later-stage tumours 
[27]. Even though comorbidity has generally been associated 
with so-called “death due to causes other than cancer”, several 
authors reported increased cancer-specific mortality in comor-
bid patients as well [41–43]. The question is, though, whether 
comorbidities may influence the histological features of 
cancer. It seems possible that chronic inflammatory state, 
hyperinsulinemia or immunosuppression are associated with 
more aggressive cancer growth and higher grade [43–45]. 
On the other hand, commonly prescribed drugs, such as non-
-steroid anti-inflammatory agents or statins, are considered to 
be protective against cancer [46–48].
Another concern while dealing with older, comorbid pa-
tients is the choice of treatment. According to a recent syste-
matic review, some of the older cancer patients themselves 
considered comorbidity as an important reason for declining 
cancer treatment [49]. As far as the physicians’ decisions are 
concerned, a common pattern, observed by most researchers, 
is a higher rate of disqualifications from surgery in co-
morbid patients [50, 51]. The question is, however, whether 
older patients with comorbidity are in fact at a higher risk 
of developing postoperative complications, and if so, which 
comorbidities are important. Unfortunately, regarding older 
cancer patients, data about its impact on surgical treatment 
effects are scarce. Most of the authors present data for patients 
of all ages. Yvette et al., who analysed 8583 gastrointestinal 
cancer patients from the Netherlands, found several comor-
bidities derived from CCI (cardiac disease, vascular disease 
and previous malignancy in colon cancer; vascular disease 
in rectal cancer) to be independent risk factors for 30-day 
mortality according to multivariate logistic regression analysis 
[52]. In another large study from the Netherlands (4911 colon, 
2674 rectal, 2385 NSCLC and 8501 breast cancer patients), 
Janssen-Heijnen found that several complications occurred 
more often in patients with certain comorbidities, but none 
of them turned out to be significant in the multivariate logistic 
regression analysis [53]. Analysing the results of 214 patients 
undergoing gastrectomy, Hamakawa et.al. showed that only 
pulmonary (OR = 2.69) and vascular disease (OR = 5.46) were 
significantly associated with postoperative complications in 
the multivariate analysis [54]. Wang et al. reported that among 
1,657 patients undergoing laparoscopy-assisted total gastrec-
tomy the presence of comorbidity (≥1 coexisting disease) was 
a risk factor for local (OR = 1.20) and systemic complications 
(OR = 1.24). They also found specific diseases such as diabetes 
mellitus, anaemia, and pulmonary and renal disease to be the 
risk factors for abdominal bleeding, anastomotic leakage and 
pneumonia [53]. Nevertheless, generalising such results for the 
population of elderly people may be misleading. Kim et al., who 
have analysed the results of patients after laparoscopy-assisted 
distal gastrectomy found that in all the patients included, 
comorbidity was a predictive factor for systemic complica-
tions in the multivariate analysis. However, after dividing the 
patients into two subgroups (1: <60 y, 2: ≥60 y), comorbidity 
remained a significant risk factor (OR = 3.32) only in patients 
aged ≥60 [55]. In a study based on Surveillance, Epidemiology, 
and End Results–Medicare Registry, which included 149,622 
patients aged 75 or more, CCI ≥3 was found to be a risk factor 
for 30-day readmission after colorectal cancer surgery (OR 
= 1.27) [56]. Regarding the Polish population, the authors of 
this review performed a logistic regression analysis among 600 
individuals aged ≥65 undergoing elective high risk abdominal 
surgeries (60% of cancer patients) and found psychiatric (OR 
= 4.4) and kidney disease (OR = 2.74) to be the independent 
risk factors for 30-day mortality, and heart disease (OR = 1.67) to 
be the independent risk factor for 30-day major complications 
(unpublished data). For now, however, the variation in study 
outcomes makes it difficult to draw certain conclusions, which 
may be useful in clinical practice. 
Moreover, comorbid patients are also less likely to receive 
adjuvant therapy and to complete chemotherapy treat-
ment. According to existing data, comorbidity may predispose 
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to development of chemotherapy-related toxicity, so they 
often receive a reduced chemotherapy dose [57–60]. To assess 
the pharmacological treatment safety, however, data from clinical 
trials would be most relevant. Even though the American Society 
of Clinical Oncology (ASCO), Friends of Cancer Research, and 
the US Food and Drug Administration recently recommended 
changing the criteria used to exclude comorbid patients from 
cancer clinical trials, the presence of comorbidities is still adversely 
associated with trial discussions, offers and participation [61]. 
Conclusions
Comorbidity is common in older cancer patients. Its prevalen-
ce, however, is difficult to determine and varies by cancer site. 
There is no single reason for which comorbidity and cancer 
coexist, but chronic diseases and cancer are both common in 
older age and share many risk factors. Also, the treatment of 
one condition may be involved in the development or affect 
the course of another disease. 
There is no consensus on how comorbidity should be 
measured. Even though many comorbidity indices have been 
developed so far, no unified, widely used instrument exists. 
Patients with comorbidities have worse outcomes com-
pared to those with no such conditions. They may experience 
diagnostic and therapeutic delay and be disqualified from 
radical treatment more often. Furthermore, they are more 
likely to suffer from treatment-related complications and have 
worse overall survival.
It seems important to assess comorbidity status as a part 
of individualised oncological treatment planning. However, 
as data regarding its significance are insufficient and in many 
cases conflicting, patients with comorbidity should not be 
routinely considered as not fit enough for radical treatment. 
Therefore, to adequately address all of the concerns that have 
been raised, broader participation of older, comorbid patients 
in clinical trials is needed.
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